TWiV 1052: Clinical update with Dr. Daniel Griffin
In his weekly clinical update, Dr. Griffin discusses disease severity of RSV compared with COVID-19 and Influenza among hospitalized adults aged ≥60 years, antiviral efficacy of Molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19, Nirmatrelvir-Ritonavir and COVID-19 mortality and hospitalization among patients with vulnerability to covid-19 complications, antibiotic use among hospitalized patients with COVID-19 in the United States, one week of oral Camostat vs Placebo in nonhospitalized adults with mild-to-moderate COVID-19, assessment of the available therapeutic approaches for severe COVID-19, optimal duration of systemic Corticosteroids in COVID-19 treatment, effect of monovalent COVID-19 vaccines on viral interference between SARS-CoV-2 and several DNA viruses in patients with long-COVID syndrome, local budesonide therapy in the management of persistent hyposmia in suspected non-severe COVID-19 patients, and the safety profile and clinical and virological outcomes of Nirmatrelvir-Ritonavir treatment in patients with advanced chronic Kidney disease and COVID-19.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode- Disease severity of RSV compared with COVID-19 and Influenza among hospitalized adults
- Antiviral efficacy of molnupiravir vs ritonavir-nirmatrelvir in patients with symptomatic COVID-19 (The Lancet)
- Nirmatrelvir-Ritonavir and COVID-19 mortality and hospitalization among patients with vulnerability to complications (JAMA)
- Antibiotic use among hospitalized patients with COVID-19 (OFID)
- One week of oral Camostat vs placebo in non-hospitalized adults with COVID-19
- Assessment of the available therapeutic approaches for severe COVID-19 (Nature)
- Optimal duration of systemic Corticosteroids in COVID-19 treatment (OFID)
- Effect of monovalent COVID-19 vaccines on viral interference between SARS-CoV-2 and in patients with long-COVID syndrome (Nature)
- Local budesonide therapy in the management of persistent hyposmia in suspected COVID-19 patients (JID)
- Safety profile and clinical and virological outcomes of Nirmatrelvir-Ritonavir treatment in patients with Kidney disease and COVID-19
- Contribute to our Floating Doctors fundraiser at PWB
- Letters read on TWiV 1052
- Dr. Griffin's COVID treatment summary (pdf)
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to daniel@microbe.tv
More description
In his weekly clinical update, Dr. Griffin discusses disease severity of RSV compared with COVID-19 and Influenza among hospitalized adults aged ≥60 years, antiviral efficacy of Molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19, Nirmatrelvir-Ritonavir and COVID-19 mortality and hospitalization among patients with vulnerability to covid-19 complications, antibiotic use among hospitalized patients with COVID-19 in the United States, one week of oral Camostat vs Placebo in nonhospitalized adults with mild-to-moderate COVID-19, assessment of the available therapeutic approaches for severe COVID-19, optimal duration of systemic Corticosteroids in COVID-19 treatment, effect of monovalent COVID-19 vaccines on viral interference between SARS-CoV-2 and several DNA viruses in patients with long-COVID syndrome, local budesonide therapy in the management of persistent hyposmia in suspected non-severe COVID-19 patients, and the safety profile and clinical and virological outcomes of Nirmatrelvir-Ritonavir treatment in patients with advanced chronic Kidney disease and COVID-19.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode- Disease severity of RSV compared with COVID-19 and Influenza among hospitalized adults
- Antiviral efficacy of molnupiravir vs ritonavir-nirmatrelvir in patients with symptomatic COVID-19 (The Lancet)
- Nirmatrelvir-Ritonavir and COVID-19 mortality and hospitalization among patients with vulnerability to complications (JAMA)
- Antibiotic use among hospitalized patients with COVID-19 (OFID)
- One week of oral Camostat vs placebo in non-hospitalized adults with COVID-19
- Assessment of the available therapeutic approaches for severe COVID-19 (Nature)
- Optimal duration of systemic Corticosteroids in COVID-19 treatment (OFID)
- Effect of monovalent COVID-19 vaccines on viral interference between SARS-CoV-2 and in patients with long-COVID syndrome (Nature)
- Local budesonide therapy in the management of persistent hyposmia in suspected COVID-19 patients (JID)
- Safety profile and clinical and virological outcomes of Nirmatrelvir-Ritonavir treatment in patients with Kidney disease and COVID-19
- Contribute to our Floating Doctors fundraiser at PWB
- Letters read on TWiV 1052
- Dr. Griffin's COVID treatment summary (pdf)
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to daniel@microbe.tv
Listen elsewhere
Available Results
Generated results are saved to your library for reuse and search.